Acarbose for Secondary Prevention of Cardiovascular Events in Patients With Coronary Stenting and Abnormal Glucose Tolerance

Acarbose for Secondary Prevention of Cardiovascular Events in Patients With Coronary Stenting and Abnormal Glucose Tolerance - Acarbose and Secondary Prevention after Coronary Stenting

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000140

Enrollment

300

Registered

2005-09-13

Start date

2005-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormal Glucose Tolerance

Interventions

Acarbose with a standard lifestyle modification for five years A standard lifestyle modification for five years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Within 8 weeks since implantation of coronary artery stents for stable angina pectoris or acute coronary syndrome. 2)Abnormal Glucose Tolerance according to 75gOGTT. 3)HbA1c is less than 6.5%. 4)Age is between 20 and 75 (at time of consent). 5)Patients who can give informed consent themselves in writing.

Exclusion criteria

Exclusion criteria: 1)Patients with abnormal glucose tolerance caused by other organic disorders such as pancreatitis, hemochromatosis, post pancreatectomy, hyperthyroidism, Cushing syndrome, Prader-Willi syndrome etc. 2)Patients with planned angioplasty. 3)Patients with uncontrollable congestive heart failure. 4)Less than 6 months since last episode of cerebral infarction. 5)Patients who have received medication for diabetes mellitus before. 6)AST(GOT) exceeding 100 IU/L or ALT(GPT) exceeding 100 IU/L. 7)Creatinine exceeding 2mg/dl. 8)Patients with a history of ileus or less than 6 months since celiotomy. 9)Pregnant women or those who plan pregnancy, or are in the lactation period. 10)Habitual drinker (more than 100ml/day of alcohol). 11)Patients with a history of gastrectomy. 12)Patients for whom it is impossible to follow up for 5 years. 13)Any other reason that the clinical supervisors or clinical researchers may have for considering a case unsuitable for the study.

Design outcomes

Primary

Measure	Time frame
Cardiovascular event free survival time	—

Secondary

Measure	Time frame
1)Conversion of abnormal glucose tolerance to type 2 diabetes 2)All cause of death 3)Occurrence of every cardiovascular event 4)Occurrence of in-stent restenosis 5)Regression of intimal plus medial complex of the carotid artery 6)Change in fasting, 2-hour blood glucose and insulin level 7)Change in homeostatis model assessment of insulin resistance 8)Change in HbA1c 9)Change in lipid profile 10)Change in high sensitive CRP 11)Change in Body Mass Index and body weight	—

Measure

Time frame

1)Conversion of abnormal glucose tolerance to type 2 diabetes 2)All cause of death 3)Occurrence of every cardiovascular event 4)Occurrence of in-stent restenosis 5)Regression of intimal plus medial complex of the carotid artery 6)Change in fasting, 2-hour blood glucose and insulin level 7)Change in homeostatis model assessment of insulin resistance 8)Change in HbA1c 9)Change in lipid profile 10)Change in high sensitive CRP 11)Change in Body Mass Index and body weight

—

Countries

Japan

Contacts

Public ContactMinako Katayama

Institute of Biomedical Research and Innovation Department of Clinical Research Promotion

minako.wk@gmail.com078-304-5200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026